Mass Tort brief
Federal Infant Formula Bellwethers and GLP-1 Evidentiary Gatekeeping
Reckitt secures a full federal defense verdict in premature formula claims while federal courts prepare to evaluate GLP-1 scientific testimony.
Mass Tort
Reckitt's defense verdict in the first federal infant formula trial eliminates immediate liability momentum — leaving plaintiffs dependent on pending state court cases.
BackgroundMore than 800 lawsuits are consolidated in federal multidistrict litigation alleging specialized premature infant formulas cause necrotizing enterocolitis, a severe intestinal disease. Earlier state court trials hit formula makers with large jury verdicts, making federal bellwethers critical tests for defense liability.
- The Chicago jury rejected failure-to-warn claims in Inman v. Mead Johnson, leaving the manufacturer with zero active adverse federal verdicts across MDL 3026.
- Reckitt shares climbed nearly 5% on the London Stock Exchange following the verdict, as investors priced in reduced immediate settlement pressure.
- Hundreds of parallel claims remain pending in state courts and federal multidistrict litigation against both Mead Johnson and competitor Abbott Laboratories.
Mass Tort
Upcoming Daubert hearings in the Ozempic litigation will test expert science — determining whether 4,000 stomach paralysis claims reach a jury.
BackgroundDaubert hearings allow federal judges to act as gatekeepers, excluding scientific testimony if expert methodology is deemed unreliable before a trial begins. The GLP-1 multidistrict litigation centralizes over 4,000 federal claims alleging Ozempic, Wegovy, and Mounjaro cause severe gastroparesis.
- Drugmakers Novo Nordisk and Eli Lilly seek to disqualify plaintiff experts, arguing that general causation between GLP-1 receptor agonists and permanent gastroparesis lacks scientific consensus.
- Court orders require all plaintiffs alleging drug-induced stomach paralysis to provide objective gastric emptying diagnostic tests to keep their claims active.
- An adverse Daubert ruling excluding general-causation experts would gut the litigation, forcing the dismissal of thousands of federal lawsuits.
Mass Tort
Zydus's $5.9 million settlement resolves indirect purchaser antitrust claims — chipping away at broad generic drug price-fixing litigation.
BackgroundMultidistrict litigation centralizes federal class actions alleging major generic pharmaceutical manufacturers colluded to fix prices and allocate market share across common medications. Indirect purchasers include health plans and resellers who bought drugs through intermediate distributors.
- The $5.9 million settlement in the Eastern District of Pennsylvania provides Zydus Lifesciences with a full liability release from indirect purchaser class claims.
- Generic drugmakers face lingering exposure from state attorneys general and direct purchasers, despite a steady cadence of smaller corporate settlements.
- The resolution reflects a continuing trend of individual generic pharmaceutical defendants settling out of the multi-year federal antitrust proceedings.
Mass Tort
Federal courts consolidated 28 data breach lawsuits against Cognizant TriZetto — centralizing liability for 3.4M exposed patient records.
BackgroundMultidistrict litigation consolidates similar civil cases from federal courts nationwide before a single judge to streamline discovery and pre-trial motions. TriZetto Provider Solutions supplies revenue-cycle software to health systems, storing sensitive patient billing and identification files.
- Around 28 civil class actions were transferred to Missouri federal court alleging Cognizant TriZetto maintained negligent data security and delayed breach notifications.
- Exposed patient files contain Social Security numbers, medical treatment codes, and billing identifiers, escalating statutory and identity theft damage claims.
- The centralization underscores growing mass tort exposure for healthcare technology vendors handling third-party clinical and administrative data.
Mass Tort
Mass Tort
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
